FY2025 · ended Dec 31, 2025 · Revenue $673.00M, +20.2% YoY · Filed Feb 18, 2026
Ultragenyx Pharmaceutical Inc. (RARE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $673.0 million and a net loss of $575.0 million. Free cash flow was -$472.0 million.
Revenue (TTM)
$730.00M
+15.8% vs year-ago TTM
Net income (TTM)
$-524.00M
+9.5% vs year-ago TTM
Operating cash flow (TTM)
$-437.00M
+1.9% vs year-ago TTM
Free cash flow (TTM)
$-442.00M
+1.9% vs year-ago TTM
EPS (TTM)
$-5.18
+12.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
96.63M
+4.5% vs prior year
Net cash
$701.00M
FY 2025
Operating margin
-64.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RARE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Novato, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1515673
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M |
| Operating income | -$535.0M | -$536.0M | -$569.0M | -$648.9M | -$381.7M |
| Net income | -$575.0M | -$569.0M | -$607.0M | -$707.4M | -$454.0M |
| Diluted EPS | -$5.83 | -$6.29 | -$8.25 | -$10.12 | — |
| Operating cash flow | -$466.0M | -$414.0M | -$475.0M | -$380.5M | -$338.7M |
| Free cash flow | -$472.0M | -$421.0M | -$519.0M | -$496.6M | -$411.8M |
| Total assets | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B |
| Total liabilities | $1.6B | $1.2B | $1.2B | $1.2B | $599.8M |
| Stockholders' equity | -$80.0M | $255.0M | $275.0M | $352.0M | $922.6M |
| Cash and investments | $737.0M | $745.0M | $777.5M | $896.7M | $999.1M |
| Total debt | $36.0M | $40.3M | $43.2M | $31.6M | $42.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Results of operations, Exit or restructuring costs
|
Nov 3, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 14, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 7, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Other events
|
Sep 17, 2026 | Sep 17, 2026 |
All 1001 Ultragenyx Pharmaceutical Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.